The global recombinant DNA technology market is valued at approximately USD 8,037.6 billion in 2023 and is projected to grow from USD 8,568.1 billion in 2024 to USD 1,623.52 billion by 2034, growing at a CAGR of 6.6% from 2024 to 2034.
An important research tool in biology, recombinant DNA technology allows scientists to manipulate fragments of DNA to study them in the laboratory. DNA is inserted into bacteria or yeast using a variety of methods, and the technology allows the host cell to copy the inserted DNA with its own DNA. This advancement has led to the development of proteins important in the treatment of human diseases, such as insulin and growth hormone. The ability to produce these therapeutic proteins is critical to the growth of the DNA technology industry as demand for new medical and biotech applications continues to drive growth in the recombinant DNA technology market.
The free sample includes a variety of data points ranging from trend analysis to estimates and forecasts. @ https://www.precedenceresearch.com/sample/1907
Recombinant DNA Technology Market Overview
The recombinant DNA technology market is experiencing rapid growth due to its various applications in research, medicine, agriculture, and industry. Recombinant DNA is created in a laboratory by transferring DNA from one organism to another. This allows genetic engineering to create multiple copies of genes to provide new properties (signs of disease) such as antibiotics or new colors. The importance of this technology lies in the fact that enzymes and various tests can be used to check and separate fragments of DNA, combine DNA from different species, and create genes with new functions.
However, obtaining pure DNA samples is a major challenge as plant and animal cells produce many compounds that can be pathogenic and interfere with cloning and sequencing. Scientists are taking advantage of the chemical and physical properties of various cellular molecules to isolate these compounds during DNA isolation, ensuring the success of the recombinant DNA process and enabling market expansion.
· In August 2024, Citius Pharmaceuticals, Inc. announced that shareholders of TenX Keane Acquisition (“TenX”), a publicly traded special acquisition company, had voted to approve the previously announced business combination with Citius Pharma's oncology subsidiary.
Report Scope
Report Scope
detail
Market size by 2034
US$803.76 billion
Market CAGR
6.6% from 2024 to 2034
European market share in 2023
twenty five%
Asia Pacific Market Size
18%
Key Insights
· North America region generated 51% revenue share in 2023.
· Europe region held a share of 25% in 2023.
By component, the expression systems segment gained market share in 2023.
· By application, the health and diseases segment held the largest revenue share in 2023.
To get full access to this report, please visit: https://www.precedenceresearch.com/checkout/1907
Regional Position
North America, especially the United States, is expected to hold the largest market share in the field of recombinant DNA technology due to its leading role in pharmaceutical manufacturing and significant research and development efforts. As of 2022, the United States accounts for 42.6% of the global market, producing $171.3 billion worth of pharmaceuticals. The United States is home to many major pharmaceutical companies and is the world's largest consumer and importer of pharmaceuticals, as well as the world's third-largest exporter of pharmaceuticals. Canada has adopted policies that align with scientific advances in animals and plants to promote innovation through sound decision-making.
The system encompasses new products in breeding, mutagenesis, recombinant DNA technology and gene editing, allowing it to adapt to new developments while maintaining research-based controlled techniques. Canadian regulators are working with sponsors to evaluate gene-edited variants to further foster innovation in the region.
Recent developments in the recombinant DNA technology market.
In May 2022, QIAGEN NV announced that it had signed an agreement to acquire a 96% majority stake in BLIRT SA, a Gdansk, Poland-based manufacturer of recombinant enzymes for the life sciences industry.
We value your investment, for customization please visit https://www.precedenceresearch.com/customization/1907
By product
The healthcare sector is projected to hold the largest market share in the recombinant DNA technology market due to its widespread applications in medicine and human biology. Recombinant DNA molecules are essential for producing human proteins within organisms, and cloned complementary DNA plays a key role in this process. More notably, insulin and growth hormones produced by recombinant DNA technology have been widely and effectively used in humans, with insulin currently being marketed. This technological strength continues to demonstrate its dominance in medicine, with recombinant DNA being used to develop and test important antibiotics, enabling market growth.
Beyond its dominant role in the medical sector, recombinant DNA (rDNA) technology is poised to capture the largest share in the crop sector in the coming years. The technology has revolutionized plant and animal biotechnology, enabling the study and modification of functional genes through genetic manipulation and introduction into plants and animals. To achieve these advancements, fundamental molecular biology tools such as DNA isolation and analysis, molecular cloning, quantification of gene expression, determination of gene copy number, host transformation, and introduction into plant crops are used. The application of rDNA technology in plant biotechnology indicates the potential for expansion into non-medical sectors and significant growth in the recombinant DNA technology market.
By Component
Over the next few years, the expression systems segment is expected to hold a dominant position in the recombinant DNA technology market. Recombinant DNA is produced in a laboratory environment by shifting segments of bacterial DNA and is important in gene cloning due to its widespread use. This includes expressing the human genome, creating transgenic animals, and creating insect-resistant crops. Expression systems play a vital role in this process, facilitating the production of desired proteins and superior properties, leading their control in the growth of the recombinant DNA technology market.
By Application
Health and disease applications is projected to account for the largest market share in the recombinant DNA technology sector, historically dominating and projected to be on a growth trajectory. The industry plays a major role in improving health outcomes through the development of new vaccines, medicines, diagnostics, diagnostic tools, and treatments. Impacts include the synthesis of human insulin and erythropoietin through genetically modified organisms, and the creation of experimental mutant mice for research. These advances highlight the importance of integrating DNA technology into health promotion and disease management, spurring the expansion of research.
Recombinant DNA technology has not only contributed greatly to human health, but is also increasingly being used to treat a variety of animals. Genetically modified animals are frequently used as models in biomedical research and are important in understanding the genetics of disease and development. These models are important in studying human diseases and evaluating responses to treatments. Using recombinant DNA technology to create and study transgenic animals advances our understanding of diseases and improves treatments, thereby broadening their range of applications and impact on human and animal health.
By end user
Recombinant DNA technology will have a significant impact on pharmaceutical manufacturing in the coming years. By applying microorganisms, macroorganisms, or hybrids of tumor cells and white blood cells, the technology can produce new drugs and improve the safety and efficacy of existing drugs, all at the same production costs as traditional drugs. These advancements are intended to improve drug efficacy, safety, and affordability, reflecting the development of DNA technology in the pharmaceutical market and facilitating adoption by end users.
Related Reports
· US Plasmid DNA Manufacturing Market Report 2024-2034: https://www.precedenceresearch.com/us-plasmid-dna-manufacturing-market
Viral Vectors and Plasmid DNA Manufacturing Market Report 2024-2034: https://www.precedenceresearch.com/viral-vectors-and-plasmid-dna-manufacturing-market
Plasmid DNA Manufacturing Market Report 2024-2034: https://www.precedenceresearch.com/plasmid-dna-manufacturing-market
Market Trends
driver
The transformative impact of recombinant DNA technology on several fields
Recombinant DNA technology is currently growing due to its unique ability to enhance organisms by controlling the expression of targeted genes. This advancement has made it possible to produce safe, affordable and sufficient proteins for health and nutrition. By leveraging multiple fields, DNA copying technology can improve health, enhance nutrition and strengthen environmental protection. In agriculture, genetically modified plants have been shown to be more resistant to harmful substances, more productive and more flexible. Furthermore, recombinant medicines are being rapidly approved in the market. The widespread use of technologies such as gene therapy, gene editing and biological repair in the treatment of serious diseases has led to a significant growth in the recombinant DNA technology market.
Constraints
Challenges and risks of recombinant DNA technology
The growth of the recombinant DNA technology market faces significant challenges and risks. The spread of genetically modified organisms in the environment could destroy native species and produce resistant plants that are easily controlled. There is also a risk of bacterial cross-contamination and transfer of DNA members, spreading diseases worldwide along with associated illnesses. Also, recombinant bacterial populations, being clones, are vulnerable to diseases and pests that could wipe out the entire population. The potential emergence of “superbugs” further adds to the concerns by highlighting the limitations and risks associated with the development and use of the recombinant DNA technology market.
opportunity
Advances and Innovations Driving the Recombinant DNA Technology Market
Recombinant DNA technology has significantly improved health outcomes through the development of new vaccines and medicines, diagnostic kits, monitoring devices, and improved treatment strategies through advanced therapeutic approaches. The combination of human insulin and erythropoietin using genetically modified organisms has proven to be revolutionary. These technologies have revolutionized biological research and are providing new opportunities for innovation in the fields of genetics and biomedicine. Recombinant DNA technology has created numerous opportunities for commercial growth by engineering microorganisms, animals, and plants to produce therapeutically useful drugs, enabling the development of a range of therapeutic products with immediate effect.
· In January 2022, Thermo Fisher Scientific completed its acquisition of PeproTech, a leader in recombinant proteins, strengthening its capabilities to serve the rapidly growing cell and gene therapy market.
Key Players in the Recombinant DNA Technology Market
Pfizer
Sanofi
New England Biolabs
GlaxoSmithKline
GenScript
Thermo Fisher Scientific Inc.
Biogen Inc.
Merck
Profaqgen
Amgen
Monsanto
Market Segmentation
By product
Medicine
Treatment drugs
Human proteins
vaccine
Non-medical
Biotech crops
Specialty Chemicals
others
By Component
Expression system
Mammals
Bacteria
Yeast
o Baculovirus/insect
Cloning vectors
By Application
Health and illness
Humans
Animals
Food and Agriculture
Environment
· others
By end user
Pharmaceutical and biotechnology companies
Research Institute
· others
By Geography
· North America
Europe
Asia Pacific
· latin america
Middle East and Africa (MEA)
To get full access to this report, please visit: https://www.precedenceresearch.com/checkout/1907
USA: +1 650 460 3308 | India: +91 87933 22019 | Europe: +44 2080772818
Email: [email protected]
